Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun:150:129-42.
doi: 10.1016/j.pharmthera.2015.01.009. Epub 2015 Jan 17.

Structure and function of serotonin G protein-coupled receptors

John D McCorvy  1 , Bryan L Roth  1
Affiliations
Review

Structure and function of serotonin G protein-coupled receptors

John D McCorvy et al. Pharmacol Ther. 2015 Jun.

Abstract

Serotonin receptors are prevalent throughout the nervous system and the periphery, and remain one of the most lucrative and promising drug discovery targets for disorders ranging from migraine headaches to neuropsychiatric disorders such as schizophrenia and depression. There are 14 distinct serotonin receptors, of which 13 are G protein-coupled receptors (GPCRs), which are targets for approximately 40% of the approved medicines. Recent crystallographic and biochemical evidence has provided a converging understanding of the basic structure and functional mechanics of GPCR activation. Currently, two GPCR crystal structures exist for the serotonin family, the 5-HT1B and 5-HT2B receptor, with the antimigraine and valvulopathic drug ergotamine bound. The first serotonin crystal structures not only provide the first evidence of serotonin receptor topography but also provide mechanistic explanations into functional selectivity or biased agonism. This review will detail the findings of these crystal structures from a molecular and mutagenesis perspective for driving rational drug design for novel therapeutics incorporating biased signaling.

Keywords: 5-HT(1B); 5-HT(2B); Functional selectivity; GPCR; Serotonin; β-Arrestin.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Figures

Figure 1
Figure 1. 5-HT receptor ligands
Shown are the structures of 5-hydrotryptamine (5-HT or serotonin) and ergolines, lysergic acid diethylamide (LSD), ergotamine (ERG), and dihydroergotamine (DHE), which are ligands at all serotonin receptors. Also shown is an example triptan ligand, sumatriptan, which posseses 5-HT1B receptor selectivity and also norfenfluramine, the active metabolite of fenfluramine, which possesses 5-HT2B agonist activity.
Figure 2
Figure 2. ERG occupies both the orthosteric and extended binding sites in 5-HT1B and 5-HT2B receptors
Ergotamine (ERG) occupies two distinct sites in both the 5-HT1B and 5-HT2B receptors, the orthosteric site, where the indole nucleus of ERG resides, and the extended binding site, where the tripeptide portion is engaged.
Figure 3
Figure 3. Orthosteric sites of the 5-HT1B and 5-HT2B receptor crystal structures
Alignment of the 5-HT1B (purple) and 5-HT2B (blue) crystal structures reveals similar binding poses for ERG in the orthosteric binding pocket. A) Conserved aspartate (D3.32) forms a salt bride with protonated N6 of ERG and is also coordinated with residue 3.36. D3.32 also forms a hydrogen bond with Y7.43. B) Conserved residues, T3.37 and A5.46, engage the indole N-H portion of ERG. C) Aromatic residues F6.51, F6.52 and W6.48 involved in an edge-to-face π-π stacking with the ring system of ERG. D) Polar residues 5.43 and 6.55 involved in an interhelical hydrogen bond between TM5 and TM6, which are the putative residues for 5-hydroxy recognition of 5-HT. E) Summary of residue interactions with ERG in the orthosteric site.
Figure 4
Figure 4. Extended binding sites of the 5-HT1B and 5-HT2B receptor crystal structures
Alignment of the 5-HT1B (purple) and 5-HT2B (blue) crystal structures reveals similar yet strikingly different poses for ERG in the extended binding site of the binding pocket. A) Tripeptide portion of ERG forms similar interactions with nonpolar contacts in EL2 and residue 7.35 B) Rotamer state of tripeptide phenyl differs depending on presence of methionine at either 5.39 (5-HT2B) or 6.58 (5-HT1B) C) TM5 is pushed toward TM6 in 5-HT2B receptor compared to the 5-HT1B receptor, likely a result of the tripeptide phenyl rotamer state D) Summary of residue interactions with ERG in the extended binding site.
Figure 5
Figure 5. Microswitch trigger motifs of the 5-HT1B and 5-HT2B receptor crystal structures
The 5-HT1B (purple) and 5-HT2B (blue) crystal structures show select differences in their trigger motifs. A) Ionic lock between Asp3.49 and Arg3.50 in the DRY motif is broken in the 5-HT1B structure but intact in the 5-HT2B structure, suggestive of an inactive state. B) In the NPxxY motif, movement of Tyr7.53 toward the helical bundle is more pronounced in the 5-HT2B structure compared to the 5-HT1B structure. C) Inward movement of Phe6.44 in the P-I-F trigger motif is only present in the 5-HT1B structure. D) Sodium (purple) in the sodium site in the DOR (orange) aligned with 5-HT structures show a condensed or collapsed sodium pocket in both 5-HT structures.
Figure 6
Figure 6. Tripeptide portion of ERG occupies a site overlapping with the allosteric modulator, LY2119620, in the muscarinic M2 receptor
Alignment of the 5-HT2B (blue) and muscarinic M2 (green; PDB 4MQS) receptor crystal structures show that M2 orthosteric agonist iperoxo (IPX) and the ergoline nucleus of ERG occupy the same site deep in the helical bundle. Similary, the tripeptide portion of ERG and M2 allosteric modulator, LY2119620 (LY), also occupy the same site encompassing the extracellular portion of the receptor.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL. Amisulpride Is a Potent 5-HT7 Antagonist: Relevance for Antidepressant Actions in Vivo. Psychopharmacology (Berl) 2009;205:119–128. - PMC - PubMed
    1. Adham N, Romanienko P, Hartig P, Weinshank RL, Branchek T. The Rat 5-Hydroxytryptamine1B Receptor Is the Species Homologue of the Human 5-Hydroxytryptamine1D Beta Receptor. Mol Pharmacol. 1992;41:1–7. - PubMed
    1. Allen JA, Roth BL. Strategies to Discover Unexpected Targets for Drugs Active at G Protein-Coupled Receptors. Annu Rev Pharmacol Toxicol. 2011;51:117–144. - PubMed
    1. Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M, et al. Discovery of Beta-Arrestin-Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy. Proc Natl Acad Sci U S A. 2011;108:18488–18493. - PMC - PubMed
    1. Almaula N, Ebersole BJ, Ballesteros JA, Weinstein H, Sealfon SC. Contribution of a Helix 5 Locus to Selectivity of Hallucinogenic and Nonhallucinogenic Ligands for the Human 5-Hydroxytryptamine2A and 5-Hydroxytryptamine2C Receptors: Direct and Indirect Effects on Ligand Affinity Mediated by the Same Locus. Mol Pharmacol. 1996a;50:34–42. - PubMed

MeSH terms

-